OPHLY:OTCMKTS
Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
4,71Â USD
arrow_downward
-0,42%(-0,020) 1d
8 d’oct., 16:00:00 GMT-4 · USD
search
Tots els sĂmbols
| SĂmbol | Preu | Canvi | Percentatge de canvi |
|---|
insights_autoS'estan generant les estadĂstiques principals per a OPHLY...
Obre
4,76Â USD
Alt
4,76Â USD
Baix
4,65Â USD
CapitalitzaciĂł borsĂ ria
1,13Â B
Volum mitjĂ
58,98Â k
Volum
45,16Â k
Alt 52 setmanes
5,75Â USD
Baix 52 setmanes
3,81Â USD
VersiĂł beta
0,21
Accions en circulaciĂł
1496,23Â M
Nombre d'empleats
4Â k
Obre
4,76Â USD
Alt
4,76Â USD
Baix
4,65Â USD
CapitalitzaciĂł borsĂ ria
1,13Â B
Volum mitjĂ
58,98Â k
Volum
45,16Â k
Alt 52 setmanes
5,75Â USD
Baix 52 setmanes
3,81Â USD
VersiĂł beta
0,21
Accions en circulaciĂł
1496,23Â M
Nombre d'empleats
4Â k
NotĂcies
De fonts web i partners de notĂcies
Perfil
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
Sobre Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
Conseller delegatGyo Sagara | Gyo Sagara
Empleats4,21Â k
FundaciĂł1717
Seu principalOsaka, Prefectura d'Osaka, JapĂł
Sector-
Lloc webono-pharma.com